Mepivacaine

Generic name: Mepivacaine hydrochloride

Category: Amide local anesthetic; commonly used as a plain vasoconstrictor-free dental anesthetic

Common brand names: Scandonest 3% Plain, Carbocaine, Polocaine, Mepivastesin. Brand availability, cartridge volume, and formulation vary by country.

This article is for dental education only. Mepivacaine should be used only by trained clinicians who understand local anesthetic dose calculation, aspiration technique, intravascular injection risk, medical history assessment, and emergency management of local anesthetic systemic toxicity. A vasoconstrictor-free anesthetic is not automatically risk-free; the total milligram dose still matters.

Mepivacaine is an amide local anesthetic used in dentistry for infiltration anesthesia and nerve blocks. The most common dental version is mepivacaine 3% plain, meaning it does not contain epinephrine/adrenaline.

It is clinically useful when a dentist wants to avoid or minimize vasoconstrictor exposure, for example in selected cardiovascular or epinephrine-sensitive situations.

The key limitation is that plain mepivacaine usually provides less hemostasis and often shorter duration than anesthetic solutions containing epinephrine.

• Best use: dental local anesthesia when a vasoconstrictor-free option is preferred
• Common dental context: infiltration anesthesia, nerve blocks, restorative dentistry, periodontal care, short procedures
• Main advantage: useful plain anesthetic without epinephrine-related palpitations or hemostatic vasoconstriction
• Main limitation: no epinephrine-assisted hemostasis and often shorter duration than lidocaine/articaine with epinephrine
• Clinical priority: calculate dose carefully because 3% mepivacaine contains 54 mg per 1.8 mL cartridge

• Local infiltration anesthesia for short restorative procedures
• Inferior alveolar, mental, infraorbital, and other dental nerve blocks
• Dental procedures in selected patients where epinephrine should be avoided or minimized
• Periodontal procedures and scaling when soft-tissue anesthesia is needed
• Supplemental anesthesia when vasoconstrictor exposure should be limited
• Procedures where hemostasis is not a major requirement
• Alternative to epinephrine-containing anesthetics in selected anxious or cardiovascularly sensitive patients after assessment

Example only: A common dental formulation is mepivacaine 3% plain. This means 30 mg/mL. One 1.8 mL cartridge contains about 54 mg mepivacaine.

A commonly referenced dental maximum is 6.6 mg/kg, equivalent to about 3 mg/lb, with a total adult maximum of 400 mg per dental sitting.

For a 70 kg healthy adult, 6.6 mg/kg equals 462 mg, but the 400 mg adult cap becomes the limiting value. Since one 1.8 mL cartridge contains about 54 mg, 400 mg equals about 7.4 cartridges by mepivacaine calculation.

The practical limit may be lower depending on age, body weight, liver function, pregnancy, anxiety, medical status, injection site, repeated injections, whether other local anesthetics were used, and whether prolonged anesthesia is really necessary.

• Known hypersensitivity to mepivacaine or other amide local anesthetics
• Use beyond maximum safe dose or without ability to manage toxicity
• Unsafe injection technique or suspected intravascular injection
• Severe liver disease or markedly impaired metabolism requiring dose reduction or medical input
• Severe cardiovascular instability where any systemic local anesthetic toxicity would be poorly tolerated
• Use in very young pediatric patients unless local labeling and clinician training support safe dosing
• Known history of serious local anesthetic reaction without clarification
• Procedures needing strong hemostasis, where plain mepivacaine may be a poor choice

• Local anesthetic systemic toxicity: may occur after overdose, rapid absorption, repeated dosing, or intravascular injection.
• Early toxicity signs: metallic taste, circumoral numbness, tongue numbness, tinnitus, dizziness, agitation, confusion, visual disturbance, tremor, or slurred speech.
• Severe toxicity: seizures, reduced consciousness, respiratory depression, arrhythmia, hypotension, cardiovascular collapse, or cardiac arrest.
• No epinephrine support: plain mepivacaine provides less local vasoconstriction, so bleeding control and duration may be less predictable than epinephrine-containing solutions.
• Dose concentration: 3% mepivacaine contains more anesthetic per cartridge than 2% lidocaine; fewer cartridges may reach the maximum dose.
• Methemoglobinemia: rare cases can occur with local anesthetics; risk may increase with oxidizing medicines or susceptible patients.
• Children and low body weight adults: dose must be calculated carefully because toxicity can occur with fewer cartridges.

Plain mepivacaine is often chosen to avoid epinephrine effects, but it still has a toxicity ceiling. The clinical mistake is to treat “no epinephrine” as “unlimited anesthetic.” Always calculate the total mepivacaine dose in milligrams.

• Other local anesthetics: total anesthetic dose is additive and increases toxicity risk.
• Class I antiarrhythmic drugs: may have additive cardiac effects with local anesthetics.
• Medicines associated with methemoglobinemia: nitrates, nitrites, dapsone, sulfonamides, some antimalarials, nitrofurantoin, phenazopyridine, and other oxidizing agents may increase risk.
• CNS depressants or sedatives: may complicate recognition and monitoring of neurologic symptoms after injection.
• Hepatic impairment or medicines affecting liver metabolism: may increase concern with repeated or high-dose local anesthetic exposure.
• General anesthetics: may change cardiovascular or respiratory safety monitoring needs.
• Other dental anesthetics used the same day: must be included in total local anesthetic planning.

• Temporary numbness of lip, cheek, tongue, or soft tissues
• Injection-site pain, bruising, or hematoma
• Dizziness or lightheadedness, sometimes related to anxiety or vasovagal reaction
• Headache, nausea, or mild drowsiness
• Prolonged numbness or altered sensation requiring follow-up
• Rare allergy to amide local anesthetics
• Rare methemoglobinemia with cyanosis, shortness of breath, fatigue, or abnormal oxygen saturation
• Rare but serious: seizure, arrhythmia, respiratory depression, cardiovascular collapse, severe systemic toxicity
• Post-anesthetic lip, cheek, or tongue biting injury

• Do not chew food until the numbness has worn off to avoid biting the lip, cheek, or tongue.
• Children should be supervised while numb because they may bite or suck numb tissues.
• Tell the dentist about liver disease, heart disease, pregnancy, previous anesthetic reactions, fainting, persistent numbness, and all medications.
• Report any history of blue lips, breathing problems, or methemoglobinemia after medications or anesthetics.
• Seek urgent help for breathing difficulty, facial swelling, throat swelling, severe dizziness, seizure, chest pain, collapse, or blue/gray skin color.
• Contact the clinic if numbness lasts unusually long, altered sensation persists, swelling worsens, severe pain develops, or infection signs appear.

Mepivacaine 3% plain is useful when the dentist wants anesthesia without epinephrine, but it is not the best choice when strong bleeding control or long pulpal anesthesia is needed. Remember the practical number: one 1.8 mL cartridge contains about 54 mg.

• Metallic taste, circumoral numbness, tinnitus, visual disturbance, agitation, confusion, tremor, slurred speech, or seizure after injection
• Severe dizziness, fainting, collapse, or altered consciousness
• Irregular heartbeat, chest pain, severe hypotension, or cardiovascular collapse
• Difficulty breathing, wheezing, facial swelling, throat swelling, or suspected allergic reaction
• Blue/gray skin color, shortness of breath, fatigue, or oxygen saturation that does not improve with oxygen
• Persistent numbness, tingling, altered sensation, or neurologic symptoms after anesthesia
• Uncontrolled bleeding, expanding hematoma, or rapidly increasing swelling
• Any suspected local anesthetic systemic toxicity requiring emergency management

• Lidocaine + Epinephrine
• Articaine + Epinephrine
• Prilocaine
• Bupivacaine + Epinephrine
• Epinephrine / Adrenaline
• Felypressin
• Topical lidocaine
• Lipid emulsion therapy for severe local anesthetic systemic toxicity

Mepivacaine is an amide local anesthetic commonly used in dentistry as a 3% plain vasoconstrictor-free solution. It is useful when epinephrine should be avoided or minimized, but it provides less hemostasis and may have shorter duration than epinephrine-containing solutions. Safe use depends on patient assessment, milligram-based dose calculation, aspiration, slow injection, awareness of additive local anesthetic dosing, recognition of toxicity signs, and clear post-anesthesia advice. The key dental habit is to remember that one 1.8 mL cartridge of 3% mepivacaine contains about 54 mg.